Thrombolysis and thrombectomy in patients treated with dabigatran with acute ischemic stroke: Expert opinion

H. C. Diener, R. Bernstein, K. Butcher, B. Campbell, G. Cloud, A. Davalos, S. Davis, J. M. Ferro, M. Grond, D. Krieger, G. Ntaios, A. Slowik, E. Touzé

Research output: Contribution to journalArticleResearchpeer-review

43 Citations (Scopus)

Abstract

© 2016, © 2016 World Stroke Organization. Systemic thrombolysis with rt-PA is contraindicated in patients with acute ischemic stroke anticoagulated with dabigatran. This expert opinion provides guidance on the use of the specific reversal agent idarucizumab followed by rt-PA and/or thrombectomy in patients with ischemic stroke pre-treated with dabigatran. The use of idarucizumab followed by rt-PA is covered by the label of both drugs.
Original languageEnglish
Pages (from-to)9-12
JournalInternational Journal of Stroke
Volume12
Issue number1
DOIs
Publication statusPublished - 1 Jan 2017

Keywords

  • dabigatran
  • idarucizumab
  • Ischemic stroke
  • rt-PA
  • thrombectomy
  • thrombolysis

Fingerprint

Dive into the research topics of 'Thrombolysis and thrombectomy in patients treated with dabigatran with acute ischemic stroke: Expert opinion'. Together they form a unique fingerprint.

Cite this